Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.
Industry, Sector and Symbol:
Capitalization:- Market Cap: $28.8 million
- Outstanding Shares: 27,697,000
Average Prices:- 50 Day Moving Avg: $1.06
- 200 Day Moving Avg: $1.25
- 52 Week Range: $0.88 - $1.70
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.32
- P/E Growth: -0.03
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.24 per share
- Price / Book: 4.33
Profitability:- Return on Equity: -220.52%
- Return on Assets: -118.36%
Debt:- Current Ratio: 1.85%
- Quick Ratio: 1.85%
Misc:- Average Volume: 197,177 shs.
- Beta: 1.09
- Short Ratio: 1
Frequently Asked Questions for Viking Therapeutics (NASDAQ:VKTX)
What is Viking Therapeutics' stock symbol?
Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."
How were Viking Therapeutics' earnings last quarter?
Viking Therapeutics, Inc. (NASDAQ:VKTX) posted its earnings results on Wednesday, August, 9th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. View Viking Therapeutics' Earnings History.
When will Viking Therapeutics make its next earnings announcement?
Where is Viking Therapeutics' stock going? Where will Viking Therapeutics' stock price be in 2017?
2 brokers have issued twelve-month target prices for Viking Therapeutics' shares. Their forecasts range from $5.00 to $7.00. On average, they anticipate Viking Therapeutics' stock price to reach $6.00 in the next year. View Analyst Ratings for Viking Therapeutics.
Who are some of Viking Therapeutics' key competitors?
Some companies that are related to Viking Therapeutics include Dicerna Pharmaceuticals (DRNA), Xenon Pharmaceuticals (XENE), Leap Therapeutics (LPTX), Motif Bio PLC (MTFB), Endocyte (ECYT), Avacta Group Plc (AVCT), Rexahn Pharmaceuticals (RNN), OptiBiotix Health PLC (OPTI), Aeglea BioTherapeutics (AGLE), Midatech Pharma PLC (MTPH), Akari Therapeutics PLC (AKTX), vTv Therapeutics (VTVT), Microbot Medical (MBOT), Actinium Pharmaceuticals (ATNM), pSivida Corp. (PSDV), Proteostasis Therapeutics (PTI), Imprimis Pharmaceuticals (IMMY) and KemPharm (KMPH).
Who are Viking Therapeutics' key executives?
Viking Therapeutics' management team includes the folowing people:
- Lawson Macartney Ph.D., Chairman of the Board
- Brian W. Lian Ph.D., President, Chief Executive Officer, Director
- Michael Morneau, Chief Financial Officer
- Amy Broidrick, Senior Vice President - Corporate Development
- Gregory S. Zante CPA, Vice President - Finance and Operations
- Catherine Lee Kelleher M.D., Vice President - Clinical Development
- Matthew W. Foehr, Director
- Charles A. Rowland Jr., Director
- Matthew Singleton, Independent Director
- Stephen W. Webster, Independent Director
When did Viking Therapeutics IPO?
(VKTX) raised $20 million in an initial public offering on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.
Who owns Viking Therapeutics stock?
Who bought Viking Therapeutics stock? Who is buying Viking Therapeutics stock?
How do I buy Viking Therapeutics stock?
Shares of Viking Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viking Therapeutics' stock price today?
One share of Viking Therapeutics stock can currently be purchased for approximately $1.04.
MarketBeat Community Rating for Viking Therapeutics (NASDAQ VKTX)MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Viking Therapeutics (NASDAQ:VKTX)Earnings History by Quarter for Viking Therapeutics (NASDAQ VKTX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/8/2017 | | ($0.19) | | | | | N/A |  |
| 8/9/2017 | Q2 2017 | ($0.19) | ($0.21) | | | View | Listen | |
| 3/21/2017 | Q4 2016 | ($0.20) | ($0.18) | | | View | N/A | |
| 11/10/2016 | Q316 | ($0.21) | ($0.20) | | | View | N/A | |
| 8/10/2016 | Q2 | ($0.20) | ($0.22) | | | View | N/A | |
| 5/10/2016 | Q1 | ($0.45) | ($0.40) | | | View | N/A | |
| 3/8/2016 | Q415 | ($0.44) | ($0.56) | | | View | N/A | |
| 11/5/2015 | | ($0.37) | ($0.53) | | | View | N/A | |
| 8/13/2015 | Q215 | ($0.13) | ($1.07) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Viking Therapeutics (NASDAQ:VKTX)2017 EPS Consensus Estimate: ($0.76)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.18) | ($0.18) | ($0.18) |
| Q2 2017 | 1 | ($0.20) | ($0.20) | ($0.20) |
| Q3 2017 | 2 | ($0.20) | ($0.19) | ($0.20) |
| Q4 2017 | 2 | ($0.19) | ($0.17) | ($0.18) |
(Data provided by Zacks Investment Research)
Dividend History for Viking Therapeutics (NASDAQ:VKTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Viking Therapeutics (NASDAQ:VKTX)Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 2.79%
Insider Trades by Quarter for Viking Therapeutics (NASDAQ:VKTX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/15/2016 | Matthew W Foehr | Director | Buy | 13,000 | $1.21 | $15,730.00 | |
| 4/13/2016 | Matthew W Foehr | Director | Buy | 20,000 | $1.24 | $24,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Viking Therapeutics (NASDAQ:VKTX)
Latest Headlines for Viking Therapeutics (NASDAQ:VKTX)
| Source: |
|
| Date | Headline |
|---|
 | Zacks Investment Research Weighs in on Viking Therapeutics, Inc.'s Q3 2017 Earnings (VKTX)
www.americanbankingnews.com - August 17 at 7:46 AM |
 | VKTX: Data From Phase 2 Trial of VK5211 Expected in 4Q17
finance.yahoo.com - August 15 at 8:02 AM |
| Viking Therapeutics, Inc. (VKTX) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - August 10 at 6:21 PM |
| Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 10 at 9:26 AM |
 | Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017 - PR Newswire (press release)
www.prnewswire.com - August 2 at 8:28 AM |
| Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017
finance.yahoo.com - August 2 at 8:28 AM |
| Viking Therapeutics, Inc. (VKTX) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM |
| Analysts Anticipate Viking Therapeutics, Inc. (VKTX) Will Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - July 31 at 12:28 PM |
| Corporate News Blog - Viking Therapeutics Completes Enrollment in Phase-2 study of VK5211 in Patients Recovering from Hip Fracture
finance.yahoo.com - July 14 at 9:44 AM |
 | Viking Therapeutics (VKTX) Completes Enrollment in Phase 2 Study of VK5211 - StreetInsider.com
www.streetinsider.com - July 13 at 11:15 AM |
| Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
finance.yahoo.com - July 12 at 8:56 AM |
| Zacks: Brokerages Expect Viking Therapeutics, Inc. (NASDAQ:VKTX) to Announce -$0.17 Earnings Per Share
www.americanbankingnews.com - July 7 at 9:08 AM |
| Viking Therapeutics (VKTX) Names Charles Rowland Jr. to Board - StreetInsider.com
www.streetinsider.com - July 7 at 2:42 AM |
| Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors
finance.yahoo.com - July 6 at 4:38 PM |
| Forward Pharma A/S (FWP) and Viking Therapeutics (VKTX) Financial Review
www.americanbankingnews.com - July 1 at 6:20 PM |
| VKTX Raises $4.3 Million in Gross Proceeds From Registered Direct Offering…
finance.yahoo.com - June 20 at 9:03 AM |
| Viking Therapeutics Announces $4.3 Million Registered Direct Offering
finance.yahoo.com - June 15 at 4:04 AM |
| Zacks: Brokerages Anticipate Viking Therapeutics, Inc. (VKTX) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - June 13 at 8:20 AM |
| VKTX: Potential of VK2809 in NASH Treatment Shown in Diet-Induced Mouse Model
finance.yahoo.com - June 8 at 1:51 AM |
| Maxim Group Analysts Give Viking Therapeutics Inc (VKTX) a $5.00 Price Target
www.americanbankingnews.com - June 7 at 6:14 PM |
| Viking Therapeutics (VKTX) Announces Top Line Results from In Vivo Study of VK2809 to Treat NASH - StreetInsider.com
www.streetinsider.com - June 7 at 12:44 AM |
| Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH)
finance.yahoo.com - June 7 at 12:44 AM |
 | Viking Therapeutics: The Good, The Bad, And (Maybe) The Ugly - Seeking Alpha
seekingalpha.com - May 25 at 6:37 AM |
| Analysts Anticipate Viking Therapeutics Inc (VKTX) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - May 16 at 4:04 PM |
| Maxim Group Reaffirms "Buy" Rating for Viking Therapeutics Inc (VKTX)
www.americanbankingnews.com - May 13 at 11:56 PM |
| VKTX: Multiple Data Readouts Ahead in 2017
finance.yahoo.com - May 13 at 2:44 AM |
| Viking Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update - PR Newswire (press release)
www.prnewswire.com - May 12 at 3:57 AM |
| Viking Therapeutics' (VKTX) Brian Lian on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 12 at 3:57 AM |
| Viking Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 11 at 3:13 AM |
| Viking Therapeutics Inc (VKTX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 8 at 9:41 AM |
| Viking Therapeutics to Report Financial Results for First Quarter 2017 After ...
finance.yahoo.com - May 8 at 9:03 AM |
| Viking Therapeutics (VKTX) Receives News Sentiment Score of 0.31
www.americanbankingnews.com - May 4 at 12:22 PM |
| Viking Therapeutics to Report Financial Results for First Quarter 2017 After Market Close on May 10, 2017
finance.yahoo.com - May 3 at 9:54 AM |
| Viking Therapeutics (VKTX) Earning Somewhat Negative News Coverage, Study Shows
www.americanbankingnews.com - May 1 at 3:50 PM |
| Viking Therapeutics (VKTX) Receives Media Sentiment Score of -0.08
www.americanbankingnews.com - April 27 at 12:00 PM |
| Viking Therapeutics Inc (VKTX) Expected to Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - April 26 at 12:03 AM |
| Viking Therapeutics (VKTX) Given Daily Media Impact Score of 0.31
www.americanbankingnews.com - April 24 at 10:24 AM |
| Viking Therapeutics (VKTX) Getting Very Positive News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 20 at 1:11 PM |
| Viking Therapeutics (VKTX) Receives Media Sentiment Rating of 0.29
www.americanbankingnews.com - April 17 at 10:52 AM |
| Viking Therapeutics (VKTX) Earns Media Sentiment Rating of 0.37
www.americanbankingnews.com - April 13 at 2:30 PM |
| Viking Therapeutics' (VKTX) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - March 31 at 11:53 AM |
| Brokerages Expect Viking Therapeutics Inc (VKTX) to Announce ($0.18) EPS
www.americanbankingnews.com - March 29 at 12:20 PM |
| Viking Therapeutics to Present at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference
finance.yahoo.com - March 28 at 8:25 AM |
| Equities Analysts Offer Predictions for Viking Therapeutics Inc's FY2019 Earnings (VKTX)
www.americanbankingnews.com - March 27 at 9:56 AM |
| Viking Therapeutics Inc (VKTX) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - March 27 at 9:26 AM |
| Viking Therapeutics Inc (VKTX) Given a $5.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - March 26 at 9:46 PM |
| VIKING THERAPEUTICS, INC. Financials
finance.yahoo.com - March 25 at 8:12 PM |
| Viking Therapeutics Inc (VKTX) PT Set at $5.00 by Maxim Group
www.americanbankingnews.com - March 24 at 11:04 PM |
| VKTX: Results from Phase 2 Trial of VK5211 in Hip Fracture in mid-2017
finance.yahoo.com - March 24 at 3:29 PM |
| Feltl & Co. Comments on Viking Therapeutics Inc's Q1 2017 Earnings (VKTX)
www.americanbankingnews.com - March 24 at 8:05 AM |
Viking Therapeutics (VKTX) Chart for Wednesday, August, 23, 2017
